Halozyme Therapeutics Competitors and Similar CompaniesClear all

Halozyme Therapeutics's competitors and similar companies include Karyopharm Therapeutics, Blueprint Medicines, Partner Therapeutics and Rakuten Medical.

	Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.	Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies.	Blueprint Medicines Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.	Partner Therapeutics Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.	Rakuten Medical Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.
Founding Date	Founding Date 1998	Founding Date 2008	Founding Date 2011	Founding Date 2017	Founding Date 2013
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare drug development healthtech pharma	Tags Healthcare drug development life sciences oncology	Tags Healthcare drug development oncology therapy	Tags Healthcare biotech drug development oncology pharma therapy
Locations	Locations San Diego, US HQ	Locations Newton, US HQ Givatayim, IL	Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH	Locations Lexington, US HQ Boston, US Lynnwood, US	Locations San Diego, US HQ Setagaya City, JP Amsterdam, NL Ecublens, CH Taipei, TW Taipei, TW San Mateo, US
Employees	Employees 373157% increase	Employees 32516% decrease	Employees 6552% increase	Employees 1911% increase	Employees 1191% decrease
Valuation ($)	Valuation ($) 6.4 b	Valuation ($) 111.7 m	Valuation ($) 5.3 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $829.3m (FY, 2023)	Revenue (est.) $146m (FY, 2023)	Revenue (est.) $249.4m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $192.4m (FY, 2023)	Cost of goods $4.9m (FY, 2023)	Cost of goods $8.5m (FY, 2023)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $636.9m (FY, 2023)	Gross profit $141.1m (FY, 2023)	Gross profit $240.8m (FY, 2023)	Gross profit N/A	Gross profit N/A
Net income	Net income $281.6m (FY, 2023)	Net income ($143.1m) (FY, 2023)	Net income ($507m) (FY, 2023)	Net income N/A	Net income N/A
Funding
Latest funding round	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 60m (about 7 years ago)	Latest funding round $ 100m (over 5 years ago)
Total funding raised	Total funding raised $ 171.9m	Total funding raised $ 248.7m	Total funding raised $ 1.7b	Total funding raised $ 60m	Total funding raised $ 451.9m